Claim Missing Document
Check
Articles

Found 22 Documents
Search

Pengaruh Terapi OAT (Obat Anti Tuberkulosis) dan Faktor Risiko Terhadap Kejadian Hepatotoksisitas pada Pasen TB Paru di RSUD Pasar Rebo: The Effect of OAT Therapy (Anti-Tuberculosis Drugs) and Risk Factors on the Incident of Hepatotoxicity in Pulmonary TB Patients at Pasar Rebo Regional Hospital Sari, Dini Permata; Sitompul, Rosna Elfrina
Jurnal Surya Medika (JSM) Vol. 11 No. 3 (2025): Jurnal Surya Medika (JSM)
Publisher : Institute for Research and Community Services Universitas Muhammadiyah Palangkaraya

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.33084/jsm.v11i3.10427

Abstract

Tuberkulosis Paru (TB Paru) merupakan salah satu penyakit menular yang masih menjadi permasalahan kesehatan global, dengan terapi utama menggunakan Obat Anti Tuberkulosis (OAT). Meskipun efektif, penggunaan OAT sering dikaitkan dengan risiko hepatotoksisitas, yaitu kerusakan hati yang ditandai dengan peningkatan kadar enzim hati (SGOT dan SGPT). Penelitian ini bertujuan untuk mengetahui pengaruh terapi OAT dan faktor risiko terhadap kejadian hepatotoksisitas pada pasien TB Paru di RSUD Pasar Rebo. Penelitian ini menggunakan desain cross-sectional dengan pendekatan kuantitatif terhadap 79 pasien yang memenuhi kriteria inklusi dan eksklusi. Data diperoleh melalui rekam medis dan kuesioner, kemudian dianalisis menggunakan uji chi-square untuk melihat hubungan antara variabel independen dengan variabel dependen. Hasil penelitian menunjukkan bahwa terdapat hubungan yang signifikan antara terapi OAT dan kejadian hepatotoksisitas. Selain itu, faktor-faktor risiko seperti usia lanjut, konsumsi alkohol, riwayat penyakit hati, dan penggunaan obat lain juga menunjukkan hubungan yang signifikan terhadap peningkatan risiko hepatotoksisitas. Berdasarkan temuan ini, disimpulkan bahwa terapi OAT dan faktor risiko berpengaruh terhadap kejadian hepatotoksisitas, sehingga diperlukan pemantauan fungsi hati secara berkala dan mengidentifikasi risiko sejak awal terapi untuk mencegah komplikasi yang lebih berat serta meningkatkan keberhasilan pengobatan TB.
DRUG THERAPY IN PATIENTS WITH GRADE 4 DEXTRA HIP OSTEOARTHRITIS WITH COMORBID HYPERTENSION AND TYPE 2 DIABETES MELLITUS Astiani, Rangki; Piter, Piter; Anggraeni, Ria; Luthfiana, Farisa; Sari, Dini Permata; Ramatillah, Diana Laila; Khan, Khasif
SOCIAL CLINICAL PHARMACY INDONESIA JOURNAL Vol 10, No 2 (2025)
Publisher : Universitas 17 Agustus 1945 Jakarta

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.52447/scpij.v10i2.8977

Abstract

Osteoarthritis (OA) is a chronic degenerative disease that affects the joints, especially heavy joints such as the knees and hips. OA often causes chronic pain and limited mobility, which is even more complex when accompanied by comorbid hypertension and type 2 diabetes mellitus. These comorbidities increase the risk of pharmacotherapy side effects and drug interactions, requiring a multidisciplinary approach and careful clinical pharmacy monitoring. The purpose of this report is to review the pharmacotherapy management of grade 4 OA Hip Dextra with comorbid HT and DMT2, assessing the safety, effectiveness, and role of clinical pharmacists in therapy optimization. A retrospective case study was conducted by analyzing the patient's medical records, including anamnesis, physical examination, laboratory, pharmacological therapy, and clinical response. The analysis was conducted based on the national guidelines of the Indonesian Ministry of Health, the 2021 National Formulary, PERKENI 2023, and PAPDI 2021. The patient was given combination therapy of NSAIDs, analgesics, prophylactic antibiotics, muscle relaxants, gastric protection, and supplementation for anemia. Therapeutic adjustments were made according to the patient's response and laboratory parameters. Clinical pharmacy monitoring ensures pain control, mobility, hemoglobin, and blood sugar. A multidisciplinary approach based on national guidelines has been shown to improve the safety and effectiveness of OA therapy with multiple comorbidities.